logo

PHARMACOLOGY - Angiotensin-Converting Enzyme | Assignment

8 Pages1240 Words42 Views
   

Added on  2020-03-04

About This Document

The assignment is based on PHARMACOLOGY in which we will explain the following topics related to the assignment - Elastase-2 in regulating Circulatory Sympathovagal balance, angiotensin in promoting atherosclerotic lesions, and the angiotensin-converting enzyme.

PHARMACOLOGY - Angiotensin-Converting Enzyme | Assignment

   Added on 2020-03-04

ShareRelated Documents
Running head: PHARMACOLOGYPharmacologyName of the studentUniversity nameAuthor’s name
PHARMACOLOGY - Angiotensin-Converting Enzyme | Assignment_1
1PHARMACOLOGYTable of contents1. Elastase-2 in regulating Circulatory Sympathovagal balance.....................................................22. Angiotension II in promoting atherosclerotic lesions..................................................................23. Angiotension converting enzyme................................................................................................3Articles referenced...........................................................................................................................4References........................................................................................................................................6
PHARMACOLOGY - Angiotensin-Converting Enzyme | Assignment_2
2PHARMACOLOGY1. Elastase-2 in regulating Circulatory Sympathovagal balanceThe roles of Angiotensin-Converting Enzyme (ACE) inhibitors in treating arterialhypertension, congestive heart failure, and other cardiovascular diseases have beendocumented well. However, recent study as well as research has shown that treatingpatients with appropriate doses of ACE inhibitors did not result in permanent attenuationAngiotension plasma levels (Daugherty et al. 2000).Angiotensin-2 generation by ELA-2 was checked in both in-vivo and ex-vivo mesenterichearts. However, the role of ELA-2 is in-vivo regulation of the cardiac cycle by bringingabout alternative constriction and relaxation of the arterioles in debatable (Becari et al.2017).In order to arrive at a suitable conclusion knockout mouse for ELA-2 gene was comparedwith a wild type mouse. Test such as echocardiography was used to access cardiacoutput, stroke volume. Moreover, cardiac indexes, ventricular wall thickness, ventricularareas along with collagen density were studied histologically (Daugherty et al. 2000).The ELA-2 knockout mice depicted symptoms of bradycardia, which could be related tothe mutation caused in the gene synthesizing Elastase-II. This could be related to thedecrease in the cardiac inhibitory function of Angiotensin –II on parasympatheticfunction (Winkelmayer et al. 2006).2. Angiotension II in promoting atherosclerotic lesionsIncreased plasma concentrations of Angiotension could be related to development ofatherosclerotic lesions. The lesions were majorly lipid-laden macrophages andlymphocytes (Daugherty et al. 2000).
PHARMACOLOGY - Angiotensin-Converting Enzyme | Assignment_3

End of preview

Want to access all the pages? Upload your documents or become a member.

Related Documents
Assignment On Pharmacology
|6
|1658
|118

Angiotensin-converting Enzyme Name: Institution: Date:.
|7
|432
|94

Nursing Management of Hypertension
|6
|1308
|122

Captopril: a potent drug which is a competitive inhibitor on the angiotensin converting enzyme
|5
|1792
|195

Role of RAAS in Cardiovascular System | Essay
|5
|1258
|25

Drug Protocol Development for Atorvastatin in Hypercholesterolemia
|9
|2418
|225